DE-CSC
17.11.2020 13:02:04 CET | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division warning consumers that simple URL typos could lead to significant online fraud, counterfeit goods, and cyber crime during the holiday shopping season. The company identified and analyzed registered domain typos (misspellings) associated with the 10 largest online shopping brands in the world and found that over 70% of the 1,553 registered domain typos appear to be owned by third parties.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005233/en/
According to CSC’s new research , these third-party owned domains receive over five million visitors annually. In addition, 40% of these domains are using domain privacy services to mask or hide their ownership and identity, and close to 48% are configured with MX (mail) records that can be used for phishing and to intercept email. In its blog, CSC offers tips to both brand owners and consumers to protect themselves against fraudulent web properties and content.
A deep dive of the top 100 most visited typo domains shows they are being used in this manner:
- 38% are pointing to advertising-related and pay-per-click web content, which can be used to spread malware via domain parking services
- 27% had no live web content, yet 37% were configured to send and receive email with MX records
- 15% were engaged in affiliate referrals, which means the brand owner could be targeted for unauthorized affiliate activity resulting in loss of revenue
- 12% were pointing at shopping-related web content, which indicates that consumers could engage with nefarious retailers selling counterfeit goods while brand owners lose revenue
- 8% were pointing toward malicious web content e.g., malware
During the holiday shopping season, just one hour of downtime can cost a business over $500,000 in lost revenue*. Despite this, many global eCommerce and shopping companies are still lacking basic domain security measures that could prevent this from happening. For instance, only 16% of the top 500 global eCommerce and shopping domains leverage domain name system (DNS) hosting redundancy, which could secure their online presence from a distributed denial of service (DDoS) attacks. In addition, only 18% use registry locks that prevent DNS hijacking attacks that could redirect consumers to alternate websites. Lastly, 40% of retailers do not use enterprise-class domain registrars. This is partially explained by the fact that 40% of the observed domains still rely on retail registrars that typically don’t provide advanced domain security features.
“ In light of the global pandemic, both consumers and leading brands have embraced online shopping as we head into the 2020 holiday season. As such, we wanted to call attention to how brands and consumers are at increased risk for a multitude of threat vectors associated with online fraud, counterfeits, revenue leakage and many other cyber criminal activities this year,” says Ihab Shraim, chief technology officer for CSC. “As evidenced by the sheer number of mail-in votes in the U.S. election, consumers are looking for safe alternatives to in-person interactions, and it’s important for brands to not only provide those digital channels, but also ensure they are secure from online threat vectors.”
“We’re delighted that companies like CSC are advocating for companies and online brands to put the necessary security protocols in place to protect not only their brand reputation, but their consumers, from online fraud and cyber crime,” says Daniel Eliot, director of Education and Strategic Initiatives at the National Cyber Security Alliance (NCSA). “The NCSA's mission is to educate consumers and businesses about these credible risks, and the importance of using recommended cyber security best practices. CSC’s research is also an important part of advocating for consumers, and showing the pervasive risk of these cyber attacks and fraudulent domains.”
Additional resources:
- Blog post
- Consumer tips infographic
*gremlin.com/ecommerce-cost-of-downtime/
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system, digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005233/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
